Tessera Therapeutics Strikes $150M Partnership with Regeneron for Gene Writing Therapy
Tessera Therapeutics has partnered with Regeneron to develop and commercialize TSRA-196, an in vivo gene writing therapy for alpha-1 antitrypsin deficiency (AATD).
Regeneron is investing $150 million in Tessera, including upfront cash and equity.
Tessera may receive up to $125 million more in milestone payments, bringing the total deal value to $275 million.
Both companies will share development costs and future profits equally.
Tessera is preparing to submit an IND and CTA for TSRA-196 to the FDA by the end of 2025.
Regeneron will lead global development and commercialization if initial clinical results are promising.